Dianthus Therapeutics Inc. 宣布,其候选药物 DNTH312 在非人灵长类动物(NHPs)研究中,显示出与 Povetacicept 相似的免疫球蛋白降低能力。这一发现表明,DNTH312 在调节免疫反应方面具有潜在的治疗价值。该研究的详细数据尚未完全公布,但初步结果已为后续的临床开发提供了有力支持。
Dianthus Therapeutics Inc. 宣布,其候选药物 DNTH312 在非人灵长类动物(NHPs)研究中,显示出与 Povetacicept 相似的免疫球蛋白降低能力。这一发现表明,DNTH312 在调节免疫反应方面具有潜在的治疗价值。该研究的详细数据尚未完全公布,但初步结果已为后续的临床开发提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.